New hope for tough leukemia? early trial of debio 1562M begins
NCT ID NCT06969430
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This early-phase trial is testing a new drug called Debio 1562M in about 134 people with acute myeloid leukemia (AML) that has come back or not responded to other treatments. The study first checks safety and finds the right dose, then looks at whether the drug can shrink the cancer. It's an open-label trial, meaning everyone knows they are getting the experimental drug.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Debio 1562M (a drug given by IV infusion)
What this could lead to
If it works, this could point toward a new treatment option for people with hard-to-treat acute myeloid leukemia.
What could go wrong
This is a very early, first-in-human trial, so safety and effectiveness are not yet known. It may not work or could cause serious side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
City of Hope Comprehensive Cancer Center
RECRUITINGDuarte, California, 91010, United States
-
MD Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
-
Moffitt Cancer Center and Research Institute Hospital
RECRUITINGTampa, Florida, 33612-9416, United States
-
Roswell Park Comprehensive Cancer Center
RECRUITINGBuffalo, New York, 14203, United States
-
START Midwest
RECRUITINGGrand Rapids, Michigan, 49546, United States
-
The Ohio Sate University
RECRUITINGColumbus, Ohio, 43210, United States
-
University of Chicago
RECRUITINGChicago, Illinois, 60637, United States